Search

Displaying results 5171 - 5180 of 5449 in total
  1. Drug

    CRx-139

    go.drugbank.com/drugs/DB05744
    Experimental

    It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects.

  2. Drug

    SVV-001

    go.drugbank.com/drugs/DB06129
    Investigational

    SVV-001 has also demonstrated cancer-killing specificity 10,000 times higher than that of traditional chemotherapeutics with no overt toxicity at doses one million times higher than effective doses in

  3. Drug

    MD05

    go.drugbank.com/drugs/DB06375
    Investigational

    MD05 is a beta-tricalcium phosphate (beta-TCP) coated with recombinant human growth/differentiation factor-5 (rhGDF-5).

  4. Drug

    Cariporide

    go.drugbank.com/drugs/DB06468
    Experimental

  5. Drug

    C31G

    go.drugbank.com/drugs/DB05398
    Investigational

    C31G is a potent broad spectrum antimicrobial agent, effective against gram positive and gram negative bacteria, yeast and fungi.C31G, vaginal gel is developed by Biosyn Inc. and has commenced enrollment in a phase III pivotal clinical t...

  6. Drug

    ISIS 113715

    go.drugbank.com/drugs/DB05506
    Investigational

    ISIS 113715 is our second-generation antisense inhibitor of protein tyrosine phosphatase 1b, or PTP‑1b, for the treatment of type 2 diabetes. In early trials, ISIS 113715 induced statistically significant improvements in multiple measure...

  7. Drug

    Stamulumab

    go.drugbank.com/drugs/DB05915
    Investigational

    MYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.

  8. Drug

    Elvucitabine

    go.drugbank.com/drugs/DB06236
    Investigational

  9. Drug

    Declopramide

    go.drugbank.com/drugs/DB06421
    Experimental

  10. Drug

    Volixibat

    go.drugbank.com/drugs/DB13914
    Investigational

    If approved for use, it will be the first available agent for the treatment of NASH. … According to Shire, the pharmaceutical manufacturer of Volixibat, it has been granted fast track status by the Food and Drug Administration due to promising initial results and a need for therapeutic treatments